BioMarin Pharmaceutical Inc. completed its acquisition of Alesta Therapeutics B.V. on August 31, 2026, making Alesta a wholly owned subsidiary. The transaction was executed pursuant to a Share Purchase Agreement previously announced on August 18, 2026. BioMarin operates in the biotechnology industry, focusing on the development and commercialization of therapies for rare diseases.
